<DOC>
	<DOCNO>NCT01413503</DOCNO>
	<brief_summary>This ongoing prospective Phase II clinical trial evaluate efficacy 131I-MIBG treatment patient metastatic unresectable pheochromocytoma relate tumor .</brief_summary>
	<brief_title>A Phase II Study 131I- Metaiodobenzylguanidine ( MIBG ) Treatment Metastatic Unresectable Pheochromocytoma Related Tumors</brief_title>
	<detailed_description>1 . To assess efficacy high-dose 131I-MIBG treatment patient malignant pheochromocytoma relate tumor , basis initial examination percentage patient CR PR , percentage patient without PD 3 year initial administration 131I-MIBG therapy . 2 . To describe response rate malignant pheochromocytoma patient treat high-dose 131I-MIBG . 3 . To describe toxicity high-dose 131I-MIBG patient malignant pheochromocytoma . 4 . To describe overall survival failure-free survival malignant pheochromocytoma patient treat high-dose 131I-MIBG . 5 . To determine utility use serum level Chromogranin A tumor marker patient malignant pheochromocytoma .</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Histologic Documentation : Histologic documentation malignant pheochromocytoma relate tumor ( paraganglioma , neuroblastoma , medullary thyroid carcinoma , carcinoid tumor ) , amenable curative surgery . Any site origin malignant pheochromocytoma , include limited : adrenal , neck , thorax , abdominal , pelvis allow . Prior Treatment : No cytotoxic chemotherapy least 3 week prior highdose 131IMIBG concurrent highdose 131IMIBG . &gt; 2 week since major surgery . &gt; 4 week since completion prior radiation therapy , long measurable disease lie outside radiation port . No treatment investigational agent concurrent within 30 day highdose 131IMIBG . Patients receive previous chemotherapy radiation therapy must evidence persistent disease 123IMIBG scan elevate tumor marker measurable CT lesion receive highdose 131IMIBG . Metastases Excluding Eligibility : No patient know significant MIBGavid parenchymal brain metastasis ; leptomeningeal metastasis exclude eligibility . Hepatic metastasis exclude eligibility functionally impair liver function ( AST total bilirubin ≥ 2.5 time ULN ) . Measurable Disease Lesions accurately measure least one dimension ( long diameter record ) &gt; 10 mm measure CT scan . Lesions &lt; 10 mm diameter bone lesion presence demonstrable uptake 123IMIBG diagnostic scanning , plus elevated level tumor marker specific malignant pheochromocytoma : plasma catecholamine metanephrines , urine catecholamine metanephrines , serum chromogranin A. Lesions whose size consider nonmeasurable include follow : Bone lesion ( see ) Leptomeningeal disease Ascites Pleural/pericardial effusion Chylothorax Lesions within chest abdomen confirm pheochromocytoma biopsy 123IMIBG scanning . 131IMIBG 123IMIBG Avidity : All patient must 123IMIBG 131IMIBG wholebody scan prior therapy . Metastases must avid isotope measure gamma radiation measure ≥ twice background radiation . Subsequent 131IMIBG Therapies : Patients must pain relief SD PR prior therapy eligible another therapy . Patients PD within 9 month prior therapy exclude receive subsequent therapy . Age : ≥4 year age . Life Expectancy : great 9 month . Karnofsky Performance Status : 70 % high . Anticoagulation : Heparin , LMW heparin , coumadin , anticoagulant may use platelet count ≥ 100,000/micronL . Platelet count monitor twice weekly 131IMIBG therapy . Pregnancy &amp; Nursing : Nonpregnant nonnursing effect highdose 131IMIBG fetus/infant unknown . Second Malignancies : Patients `` currently active '' second malignancy , nonmelanoma skin cancer , eligible . Patients consider `` currently active '' second malignancy cancerfree ≥5 year . Intercurrent Illness : No patient uncontrolled intercurrent illness include limited : ongoing active infection , grade 3 4 congestive heart failure echocardiogram , nephrotic syndrome , serum albumin &lt; 3 , significant ascites pleural effusion , pulmonary function test ( FVC ) less 70 % predicted age , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Required Initial Laboratory Data ( Minimum Levels ) : Neutrophil count &gt; /= 1,000/micronL Platelet count &gt; /= 80,000/micronL AST ( SGOT ) ≤ 2.5 x ULN Total bilirubin ≤ 2.5 x ULN Creatinine ≤ 2 x ULN 1 ) Pregnancy &amp; Nursing : Nonpregnant nonnursing effect highdose 131IMIBG fetus/infant unknown . 2 ) Second Malignancies : Patients `` currently active '' second malignancy , nonmelanoma skin cancer , eligible . Patients consider `` currently active '' second malignancy cancerfree ≥5 year 3 ) Intercurrent Illness : No patient uncontrolled intercurrent illness include limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Pheochromocytoma</keyword>
	<keyword>Paraganglioma</keyword>
	<keyword>MIBG</keyword>
	<keyword>131I-MIBG</keyword>
	<keyword>Resistant</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Treatment</keyword>
	<keyword>UCSF</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Adult</keyword>
	<keyword>Oncology</keyword>
</DOC>